📰 Antonio Risitano News
Antonio Risitano News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Antonio Risitano. Real-time updates on events, politics, business and more.
December 11, 2023
Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.
May 4, 2023
Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
April 27, 2023
The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.
April 26, 2023
Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2...
April 26, 2023
Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline
April 26, 2023
Iptacopan achieved "improvement of anaemia never seen before with anti-C5s” in PNH, showed Novartis data presented at 2023 EBMT.
April 26, 2023
Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.